Sedation vs Intubation for Endovascular Stroke TreAtment Trial (SIESTA) is a prospective, randomised controlled, monocentric, two-armed, comparative trial. Patients are randomized 1 : 1 to either non-intubated state or to intubated state for endovascular stroke treatment. Otherwise, no principal differences in intensive care treatment are intended, and standard operating procedures are applied to ensure uniform management decisions in fields such as ventilation, sedation, cardio-vascular and cerebral monitoring and management.
Early recanalization is an important, if not the most important, factor concerning reconstitution of patients´ health in ischaemic stroke. This is the reason why patients with extended stroke are increasingly subjected to an endovascular stroke therapy (EST). Matter of ongoing debate is how to sedate these patients during intervention. Some clinicians prefer an intubation due to a reduction of patients´movements and therefore potentially lowering complication rates (injury by catheter, aspiration e.g.). On the other hand retrospective investigations hypothesize that general anaesthesia is associated with peri-interventional hypotension followed by poorer clinical outcome. The best anaesthaesiologic management in endovascular stroke therapy to this point of time is not known. The investigators therefore designed this study comparing intubated state with general anaesthesia vs. non-intubated state with conscious sedation during EST, focusing on patients´ outcome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a "bridging concept"
Department of Neurology, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
National Institutes of Health Stroke Scale (NIHSS) after 24 hours
Neurological improvement of NIHSS 24 hours after intervention
Time frame: 24 hours
Outcome after 3 month using the modified Rankin Scale (mRS)
Assessing the neurological outcome after 3 months with the mRS.
Time frame: 3 month
Inpatient-mortality
Time frame: Mortality-rate until timepoint of discharge, an expected average of 3 weeks.
Mortality-rate within the first 3 months after intervention.
Time frame: First 3 months after intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.